RxDoctor Payments Data

David Wilson

Endocrinology, Diabetes & Metabolism · Fort Worth, TXNPI 1922030832

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (43.9%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Lilly USA, LLC at 52.8% of the total. Reporting peaked in 2019 at $14,973 and has fallen 99.6% since, to $64 in 2025.

$22,222in general payments, 2019–2025

Across 451 payments — averaging $49.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$12K
  • Johnson & Johnson$3K
  • AstraZeneca$1K
  • Amarin Pharma, Inc.$632
  • AbbVie$518
  • Sanofi-aventis U.S. LLC$444
  • plus $4K from 38 others

What the payments were for

  • Consulting fees$3,25015%
  • Speaking & faculty fees$9,76044%
  • Travel & lodging$9494%
  • Food & beverage$8,25537%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,222 in reported general payments places this provider in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.

See all endocrinology, diabetes & metabolism providers in Texas →

Other endocrinology, diabetes & metabolism in Fort Worth

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →